[
    [
        {
            "time": "2022-09-30",
            "original_text": "凯莱英：本次限制性股票上市流通日期为9月30日，占公司总股本0.0455%。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "限制性股票",
                    "上市流通",
                    "解禁"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英：本次限制性股票上市流通日期为9月30日，占公司总股本0.0455%。",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：政策鼓励医疗器械国产替代，国产器械前景广阔。",
            "features": {
                "keywords": [
                    "政策鼓励",
                    "医疗器械",
                    "国产替代",
                    "前景广阔"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业周报：政策鼓励医疗器械国产替代，国产器械前景广阔。",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-09-30",
            "original_text": "凯莱英(002821.SZ)：11.12万股限售股将于9月30日起上市流通，解禁。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "限售股",
                    "解禁",
                    "上市流通"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：11.12万股限售股将于9月30日起上市流通，解禁。",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 1,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-09-30",
            "original_text": "凯莱英(002821.SZ)：11.122万股限制性股票9月30日解锁上市。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "限制性股票",
                    "解锁",
                    "上市"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：11.122万股限制性股票9月30日解锁上市。",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 1,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业跨市场周报：新冠呈常态化趋势，看好新冠小分子药CDMO供应商。",
            "features": {
                "keywords": [
                    "医药生物",
                    "新冠",
                    "常态化",
                    "CDMO供应商"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "新冠药物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：新冠呈常态化趋势，看好新冠小分子药CDMO供应商。",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值。",
            "features": {
                "keywords": [
                    "医药生物",
                    "景气度",
                    "竞争力",
                    "外需",
                    "诺禾致源"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "基因检测"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值。",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物：海外新冠治疗药物Q4有望获批。",
            "features": {
                "keywords": [
                    "医药生物",
                    "海外",
                    "新冠治疗药物",
                    "Q4获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "新冠药物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物：海外新冠治疗药物Q4有望获批。",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]